FDMT - 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer | Benzinga
EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT. Mr. Mehra will succeed August J. Moretti, J.D., who is retiring, and has agreed to serve in an advisory capacity to support Mr. Mehra's transition. Mr. Mehra will lead 4DMT's finance, business development, and precommercial functions and will be a member of 4DMT's Executive Team, reporting to David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
Mr. Mehra brings over 27 years of extensive leadership experience including financial, commercial, corporate strategy, and business development expertise supporting multi-billion dollar commercial-stage businesses, in addition to deep experience successfully growing and scaling emerging companies. He previously served as a senior executive at Novartis for 13 years and as CFO & CBO of publicly traded companies, including most recently Myovant Sciences Ltd., which was recently acquired (all remaining shares not already owned) by Sumitovant Biopharma for $1.7 billion.
"We are thrilled to welcome Uneek to 4DMT at an important inflection point in our company progress towards pivotal trials across multiple programs," said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. "Uneek brings valuable skillsets to 4DMT with his extensive experience and track record in biopharmaceutical finance, strategy, and transactions. His appointment reflects our commitment to unlocking the full potential of our Therapeutic Vector Evolution platform, and he will play a major role in our goal to become a fully integrated large market genetic medicines company. We thank August Moretti for his many outstanding contributions to ...